Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
On the 2025 ASCO Annual Assembly, Dr. Emre Yekedüz, a medical oncologist and analysis fellow at Dana-Farber Most cancers Institute, emphasised that the...
Dr. Alexandra Zaleta discusses how most most cancers sufferers face prior authorization delays, regardless of 95% being authorized, highlighting the necessity for reform.Many...
Dr. Breelyn Wilky, director of sarcoma medical oncology on the College of Colorado Most cancers Heart, encourages sufferers with gastrointestinal stromal tumors (GIST)...
